On January 18, 2024 Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that it will present a trials in progress poster at the upcoming 2024 ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA (Press release, Tvardi Therapeutics, JAN 18, 2024, View Source [SID1234639335]). The poster will highlight the design of the ongoing REVERTLIVER CANCER study, a Phase 1b/2 trial evaluating safety and clinical activity of TTI-101, a novel STAT3 inhibitor, as monotherapy and in combination with standard of care in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
Date: Friday, January 19, 2024
Time: 12:30 p.m. PST
Location: Moscone West, San Francisco, CA
Session Type: Trials in Progress Poster Session
Abstract Title: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Advanced Hepatocellular Carcinoma. LEARN MORE
Abstract #: TPS577
Poster Bd #: P6
The REVERTLIVER CANCER trial is currently enrolling HCC patients at top US cancer research institutes and is designed to evaluate TTI-101 across multiple lines of therapy:
TTI-101 alone for patients previously treated with up to three prior lines of systemic therapy
TTI-101 in combination with pembrolizumab (Keytruda) for patients previously treated with immunotherapy
TTI-101 in combination with atezolizumab (Tecentriq) and bevacizumab (Avastin) for treatment-naïve patients
HCC is the most common form of liver cancer; however, treatment options for the disease are limited and overall prognosis is poor, with a 5-year survival rate of 18%. TTI-101’s target, STAT3, is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment. TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3.
"We are excited to present this unique trial design that allows us to evaluate the potential of TTI-101 to enhance outcomes across 1st, 2nd, and last line HCC patients, where the current standard of care is insufficient," said Imran Alibhai, Ph.D., CEO of Tvardi Therapeutics.
For more information about the REVERTLIVER CANCER trial, please visit ClinicalTrials.gov (NCT05440708).